Clinical trials: novel agents in development in Richter transformation (RT)
| Reference . | Treatment . | Number . | ORR . | Survival . |
|---|---|---|---|---|
| Eyre et al., Lancet Haem 2021 | Acalabrutinib | N = 25 | ORR 38% CR 14% | mPFS 3.2 m mDOR 5.7 m |
| Tsang et al., Blood 2015 | Ibrutinib | N = 4 | 2 PR, 1 CR, 1 clinical benefit | Median duration on treatment 6.1 m |
| Wierda et al., ASH 2022 | Pirtobrutinib | N = 75 | ORR 52% CR 13% | mPFS 3.7 m |
| Tam et al., HemaSphere 2023 | Zanubrutinib | N = 13 | ORR 61.5% CR 15.4% | mPFS 17.3 m |
| Tam et al., HemaSphere 2023 | Zanubrutinib-tislelizumab | N = 7 | ORR 42.9% CR 14.3% | mPFS 2.9 m |
| Jain et al., Blood Adv. 2022 | Ibrutinib-nivolumab | N = 24 | ORR 42% CR 34% | mOS 13 m |
| Ding et al., Blood 2017 | Pembrolizumab | N = 9 | ORR 44% CR 11% | mOS 10.7 m |
| Armand et al., BJH 2020 | Pembrolizumab | N = 23 | ORR 13% CR 4% | mOS 3.8 m |
| Davids et al., JCO 2017 | Venetoclax | N = 7 | ORR 43% No CRs | NK |
| Davids et al., Blood 2022 | Venetoclax-EPOCH-R | N = 12 evaluable N = 20 total | ORR 75% CR 67% | mPFS is 10 m mOS is 16.3 m |
| Davids et al., ICML 2023 | R-CHOP-venetoclax | N = 25 evaluable N = 27 total | ORR 68% CR 48% | mPFS 7.2 m mOS 19.5 m |
| Mato et al., ASH 2020 | Novel BTKi, DTRMWXHS-12 (DTRM-12), everolimus and pomalidomide | N = 11 | ORR 36% | NK |
| Kater et al., ASH 2022 | Epcoritamab | N = 10 | ORR 60% CR 50% | NK |
| Carlo-Stella et al., ICML 2023 | Glofitamab | N = 11 | ORR 63.6% CR 45.5% | NK |
| Reference . | Treatment . | Number . | ORR . | Survival . |
|---|---|---|---|---|
| Eyre et al., Lancet Haem 2021 | Acalabrutinib | N = 25 | ORR 38% CR 14% | mPFS 3.2 m mDOR 5.7 m |
| Tsang et al., Blood 2015 | Ibrutinib | N = 4 | 2 PR, 1 CR, 1 clinical benefit | Median duration on treatment 6.1 m |
| Wierda et al., ASH 2022 | Pirtobrutinib | N = 75 | ORR 52% CR 13% | mPFS 3.7 m |
| Tam et al., HemaSphere 2023 | Zanubrutinib | N = 13 | ORR 61.5% CR 15.4% | mPFS 17.3 m |
| Tam et al., HemaSphere 2023 | Zanubrutinib-tislelizumab | N = 7 | ORR 42.9% CR 14.3% | mPFS 2.9 m |
| Jain et al., Blood Adv. 2022 | Ibrutinib-nivolumab | N = 24 | ORR 42% CR 34% | mOS 13 m |
| Ding et al., Blood 2017 | Pembrolizumab | N = 9 | ORR 44% CR 11% | mOS 10.7 m |
| Armand et al., BJH 2020 | Pembrolizumab | N = 23 | ORR 13% CR 4% | mOS 3.8 m |
| Davids et al., JCO 2017 | Venetoclax | N = 7 | ORR 43% No CRs | NK |
| Davids et al., Blood 2022 | Venetoclax-EPOCH-R | N = 12 evaluable N = 20 total | ORR 75% CR 67% | mPFS is 10 m mOS is 16.3 m |
| Davids et al., ICML 2023 | R-CHOP-venetoclax | N = 25 evaluable N = 27 total | ORR 68% CR 48% | mPFS 7.2 m mOS 19.5 m |
| Mato et al., ASH 2020 | Novel BTKi, DTRMWXHS-12 (DTRM-12), everolimus and pomalidomide | N = 11 | ORR 36% | NK |
| Kater et al., ASH 2022 | Epcoritamab | N = 10 | ORR 60% CR 50% | NK |
| Carlo-Stella et al., ICML 2023 | Glofitamab | N = 11 | ORR 63.6% CR 45.5% | NK |
CHOP-R, doxorubicin, vincristine, cyclophosphamide, prednisolone, rituximab; CR, complete response; EPOCH-R, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone, rituximab; m, month; mDOR, median duration of response; mOS, median overall survival; mPFS, median progression-free survival; NK, not known; ORR, overall response rate; PR, partial response.